In vitro activity: PD-1/PD-L1 Inhibitor 3 is capable of inhibiting the interaction of PD-L1 with PD-1 and with CD80. It has highly efficacious binding to PD-L1 and promotes enhanced T cell functional activity. PD-1/PD-L1 inhibitor 3 has been identified to be a potent and selective small molecule inhibitor blocking the interaction of programmed cell death protein 1 (PD-1) with its ligand protein (PD-L1) and with CD80. PD-1/PD-L1 inhibitor 3 was also found to act as an immunomodulator. In addition, PD-1/PD-L1 Inhibitor 3 was found to have highly efficacious binding to PD-L1 and promote the increased functional activities of T cells. Therefore, PD-1/PD-L1 inhibitor 3 could be regarded as a promising therapeutic treatment of cancer and infectious diseases, such as hepatitis C

Kinase Assay:

Cell Assay:

Patent, Pub. No.:WO/2014/151634